New hope in fight against Alzheimer's: Dual-Attack drug trial launches

NCT ID NCT06957418

Summary

This clinical trial aims to test whether new drugs that target tau protein in the brain can slow Alzheimer's disease progression, either alone or combined with existing amyloid-targeting treatments. It will enroll 750 adults aged 50-80 who have early signs of Alzheimer's but minimal symptoms. Participants will receive different drug combinations over 30 months while researchers monitor brain changes through scans and blood tests.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.